Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting ...

Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Travere Therapeutics Inc. Annual cash flow by MarketWatch. View TVTX net cash flow, operating cash flow, operating expenses and cash dividends.

Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.

From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global ...

Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...